Business Wire

ACAMS and ElephantThink Partner to Deliver Groundbreaking Web-Based Transaction Monitoring and Know-Your-Customer Training for ING Globally

Share

ACAMS, in partnership with artificial intelligence (AI) company ElephantThink, has successfully conceptualized and delivered its first fully online web-based compliance training program for Dutch banking group ING. The training partnership is for a multi-lingual SaaS solution offering mobile and web-based access to equip recipients with core competencies required to perform analysis, onboarding and anti-money laundering prevention roles and considered pioneering in the world of financial crime prevention training.

ING, which has a presence in over 40 countries serving over 38 million customers, places great emphasis on compliance, know your customer (KYC) / customer due diligence (CDD) and enhanced due diligence (EDD), which is reflected in the 4-year training agreement with ACAMS and ElephantThink.

Under the terms of the partnership, training is delivered digitally via e-learning on the ElephantThink Smart Learning Platform, and accessible in nine languages - English, Dutch, French, German, Italian, Romanian, Spanish, Turkish and Polish. Learners will have the ability to access the web-based learning curriculum supported by a companion mobile application which includes gamification elements to drive engagement and information retention. Qualifying ING employees will receive a verifiable digital certificate upon completion of their training.

Commenting on the training partnership, Roel Louwhoff, chief operations officer and chief transformation officer of ING, said: “As a gatekeeper to the financial system, ING has a responsibility to protect it, our customers and society against financial and economic crimes. Partnering with ACAMS to introduce their internationally recognized and certified digital training enables us to further enhance the KYC knowledge, skills and expertise of our employees in an innovative and engaging manner. This helps to fight financial economic crime, ensuring our customers can continue banking safely and securely as we empower them to stay a step ahead in life and in business.’’

Angela Salter, Interim President of ACAMS, said, “This is our first foray into delivering global web-based training to the KYC / CDD and transaction monitoring (TM) teams, and the promise of accelerated reach and efficacy is especially significant in the current environment. The commitment of ING to support a revolutionary training approach for a highly regulated and constantly evolving operating landscape cemented the success of our ground-breaking partnership with ElephantThink.”

Jack Smies, CEO of ElephantThink, said, “The mix of very high quality content from our partner ACAMS combined with our capabilities on AI, gamification and digital claims can really turbo charge people’s learning, which is reflected in the initial response and results of the training.”

Under the terms of the partnership ACAMS will make available AML, Sanctions, KYC and Transaction Monitoring programmes as well as ACAMS Certified Know Your Customer Associate (CKYCA) training at foundational and intermediate levels. These trainings are available in English, Dutch and multiple other languages, providing front-line and operations teams with the tools to perform KYC, CDD and EDD duties. ING’s sanctions, AML compliance and audit team learners will also have access to the full suite of ACAMS courses for the 2nd and 3rd lines of defence, underpinned by ACAMS’ comprehensive continuous education and alerts programme.

In a separate development, ACAMS has been granted approval by the Netherlands training registry body CRKBO to provide anti-financial crime training on a VAT free basis in the country, representing a savings of 21% on every ACAMS training course procured direct from ACAMS including its gold-standard CAMSTM Certified AML Specialist and recently launched Certified Global Sanctions Specialist (CGSS) qualifications.

About ACAMS®

ACAMS is a member of Adtalem Global Education (NYSE: ATGE), a leading workforce solutions provider headquartered in the United States. ACAMS is the largest international membership organization dedicated to enhancing the knowledge and skills of anti-money laundering (AML) and financial crime prevention professionals from a wide range of industries. Its CAMS certification is the most widely recognized AML certification among compliance professionals worldwide. Its new Certified Global Sanctions Specialist (CGSS) certification commenced in January 2020. Visit acams.org for more information.

About Adtalem Global Education

The purpose of Adtalem Global Education is to empower students to achieve their goals, find success, and make inspiring contributions to our global community. Adtalem Global Education Inc. (NYSE: ATGE; member S&P MidCap 400 Index) is a leading workforce solutions provider and the parent organization of American University of the Caribbean School of Medicine, Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, Chamberlain University, EduPristine, OnCourse Learning, Ross University School of Medicine and Ross University School of Veterinary Medicine. For more information, please visit adtalem.com and follow us on Twitter (@adtalemglobal) and LinkedIn.

About ElephantThink:

ElephantThink is an Artificial Intelligence company that focuses on algorithms and models. By applying this specifically to employee training and development they created a Smart Learning Platform. This smart learning platform can provide hyper personalization so that the learning is optimized for maximum efficiency per individual learner and is unique in that it adapts to the specific way each participant learns. By using spaced repetition of learning elements that are memory dependent, gamification to ensure user engagement and verifiable certificates and badges for user motivation and recognition ET is able to significantly improve the learner’s development. Visit elephantthink.com for more information.

Contact information

Lashvinder Kaur
lkaur@acams.org
+44 7388 264478

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom